Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice

References

• Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target 1996; 3: 455–467
   PubMed Web of Science ®Google Scholar
• Anderson AO. Structure and organization of the lymphatic system. Oxford University Press, New York 1990
   Google Scholar
• Barchfeld GL, Hessler AL, Chen M, Pizza M, Rappuoli R, Van Nest GA. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 1999; 17: 695–704
   PubMed Web of Science ®Google Scholar
• Bonanni P. Demographic impact of vaccination: A review. Vaccine 1999; 17(Suppl 3)S120–S125
   PubMed Web of Science ®Google Scholar
• Bowersock TL, HogenEsch H, Torregrosa S, Borie D, Wang B, Park H, Park K. Induction of pulmonary immunity in cattle by oral administration of ovalbumin in alginate microspheres. Immunol Lett 1998; 60: 37–43
   PubMed Web of Science ®Google Scholar
• Bowersock TL, HogenEsch H, Suckow M, Guimond P, Martin S, Borie D, Torregrosa S, Park H, Park K. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 1999; 17: 1804–1811
   PubMed Web of Science ®Google Scholar
• Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 1997; 15: 1710–1715
   PubMed Web of Science ®Google Scholar
• Chen H, Torchilin V, Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res 1996; 13: 1378–1383
   PubMed Web of Science ®Google Scholar
• Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JC, Greenberg HB, Herrmann JE. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998; 72: 5757–5761
   PubMed Web of Science ®Google Scholar
• Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006; 34: e73
   PubMed Web of Science ®Google Scholar
• Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland EJ, Borkowsky W. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis 2001; 32: 801–807
   PubMed Web of Science ®Google Scholar
• Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001; 51: 21–42
   PubMed Web of Science ®Google Scholar
• de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenburg GJ, Palache AM, Wilschut J. Mucosal immunoadjuvant activity of liposomes: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995; 13: 155–162
   PubMed Web of Science ®Google Scholar
• Doucet O, Ferrero L, Garcia N, Zastrow L. O/W emulsion and W/O/W multiple emulsions: Physical characterization and skin pharmacokinetic comparison in the delivery process of caffeine. Int J Cosmet Sci 1998; 20: 283–295
   PubMedGoogle Scholar
• Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, McDonald DM. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998; 186: 18–27
   PubMed Web of Science ®Google Scholar
• Ferreira LAM, Doucet J, Seiller M, Grossiord JL, Marty JP, Wepierre J. In vitro percutaneous absorption of etronidazole and glucose: Comparison of O/W, W/O/W and W/O systems. Int J Pharm 1995; 121: 169–179
   Web of Science ®Google Scholar
• Gallarate M, Carlotti ME, Trotta M, Bovo S. On the stability of ascorbic acid in emulsified systems for topical and cosmetic use. Int J Pharm 1999; 188: 233–241
   PubMed Web of Science ®Google Scholar
• Glueck R. Review of intranasal influenza vaccine. Adv Drug Deliv Rev 2001; 51: 203–211
   PubMed Web of Science ®Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA, Jacobson RM, Izu AE, Sakamoto D, Eiden J, Van Nest GA, Hsu HH. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999; 17: 2769–2778
   PubMed Web of Science ®Google Scholar
• Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14: 478–484
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45–S53
   PubMed Web of Science ®Google Scholar
• Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int J Pharm 2005; 297: 223–234
   PubMed Web of Science ®Google Scholar
• Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 2001; 51: 5–19
   PubMed Web of Science ®Google Scholar
• Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994; 170: 1288–1291
   PubMed Web of Science ®Google Scholar
• Kunisawa J, Okudaira A, Tsutusmi Y, Takahashi I, Nakanishi T, Kiyono H, Mayumi T. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. Vaccine 2000; 19: 589–594
   PubMed Web of Science ®Google Scholar
• Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L. A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity [corrected]. Ann Intern Med 1995; 122: 889–898
   PubMed Web of Science ®Google Scholar
• Lehr CM, Bouwstra JA, Bodde HE, Junginger HE. A surface energy analysis of mucoadhesion: Contact angle measurements on polycarbophil and pig intestinal mucosa in physiologically relevant fluids. Pharm Res 1992; 9: 70–75
   PubMed Web of Science ®Google Scholar
• Lombry C, Marteleur A, Arras M, Lison D, Louahed J, Renauld JC, Preat V, Vanbever R. Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm Res 2004; 21: 127–135
   PubMed Web of Science ®Google Scholar
• Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, Schafer DP, Russell MW. Current options for vaccine delivery systems by mucosal routes. J Control Release 1997; 48: 243–257
   Web of Science ®Google Scholar
• Morishita M, Matsuzawa A, Takayama K, Isowa K, Nagai T. Improving insulin enteral absorption using water-in-oil-in-water emulsion. Int J Pharm 1998; 172: 189–198
   Web of Science ®Google Scholar
• Nitayaphan S, Khamboonruang C, Sirisophana N, Morgan P, Chiu J, Duliege AM, Chuenchitra C, Supapongse T, Rungruengthanakit K, deSouza M, Mascola JR, Boggio K, Ratto-Kim S, Markowitz LE, Birx D, Suriyanon V, McNeil JG, Brown AE, Michael RA. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 2000; 18: 1448–1455
   PubMed Web of Science ®Google Scholar
• O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 2001; 1: 273–286
   PubMedGoogle Scholar
• O'Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: The development of MF59 emulsion and polymeric microparticles. Mol Med Today 1997; 3: 69–75
   PubMedGoogle Scholar
• Okochi H, Nakano M. Basic studies on formulation, method of preparation and characterization of water-in-oil-in-water type multiple emulsions containing vancomycine. Chem Pharm Bull 1996; 44: 180–186
   Web of Science ®Google Scholar
• Okochi H, Nakano M. Preparation and evaluation of W/O/W type emulsions containing vancomycin. Adv Drug Deliv Rev 2000; 45: 5–26
   PubMed Web of Science ®Google Scholar
• Omotosho JA, Whateley TL, Florence AT. Release of 5-fluorouracil from intramuscular W/O/W multiple emulsions. Biopharm Drug Dispos 1989; 10: 257–268
   PubMed Web of Science ®Google Scholar
• Omotosho JA, Florence AT, Whateley TL. Absorption and lymphatic uptake of 5-fluorouracil in the rat following oral administration of W/O/W multiple emulsions. Int J Pharm 1990; 61: 51–56
   Web of Science ®Google Scholar
• Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180: 970–975
   PubMed Web of Science ®Google Scholar
• Raynal S, Grossiord JL, Seiller M, Clausse D. A topical W/O/W multiple emulsion containing several active substances: Formulation, characterization and study of release. J Control Release 1993; 26: 129–140
   Web of Science ®Google Scholar
• Sally B, Ronald BM, Eduardo F-C. Calculating the potential epidemic-level impact of therapeutic vaccination on the San Francisco HIV epidemic. AIDScience 2003; 3
   Google Scholar
• Silva-Cunha A, Chéron M, Grossiord JL, Puisieux F, Seiller M. W/O/W multiple emulsions of insulin containing a protease inhibitor and an absorption enhancer: Biological activity after oral administration to normal and diabetic rats. Int J Pharm 1998; 169: 33–44
   Web of Science ®Google Scholar
• Silva-Cunha A, Grossiord JL, Seiller M. Multiple emulsions: Pharmaceutical potentiality. Multiple emulsions: Structure, properties and applications, JL Grossiordand, M Seiller. de Sante, France 1999; 279–312
   Google Scholar
• Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999; 178: 55–65
   PubMed Web of Science ®Google Scholar
• Swart PJ, Beljaars L, Kuipers ME, Smit C, Nieuwenhuis P, Meijer DK. Homing of negatively charged albumins to the lymphatic system: General implications for drug targeting to peripheral tissues and viral reservoirs. Biochem Pharmacol 1999; 58: 1425–1435
   PubMed Web of Science ®Google Scholar
• Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 1996; 14: 1677–1685
   PubMed Web of Science ®Google Scholar
• Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174: 1168–1175
   PubMed Web of Science ®Google Scholar
• Uchida T, Goto S. Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: Particle size study. Biol Pharm Bull 1994; 17: 1272–1276
   PubMed Web of Science ®Google Scholar
• Uchida T, Martin S, Foster TP, Wardley RC, Grimm S. Dose and load studies for subcutaneous and oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin. Pharm Res 1994; 11: 1009–1015
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14: 478–484
   PubMed Web of Science ®Google Scholar
• Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, Sun Y, Morein B, Akerblom L, Fuller DH, Barnett SW, Heeney JL. Comparison of immunity generated by nucleic acid-, MF59- and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance. J Virol 1999; 73: 3292–3300
   PubMed Web of Science ®Google Scholar
• Watarai S, Han M, Tana, Kodama H. Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes. J Vet Med Sci 1998; 60: 1047–1050
   PubMed Web of Science ®Google Scholar